Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

JAZZBullishIndustry Newsnews

High materiality8/10

Jazz Advances Modeyso Phase 3 for rare brain cancer with near-term SNO focus

Nov 2, 2026, 8:58 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 3 progress and new Phase 2 signals, plus SNO-presented data, can re-rate the CNS oncology franchise; interim 2027 readout is a meaningful longer-term catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Jazz Pharmaceuticals outlines progress on Modeyso and JZP3507 at SNO 2026. The Phase 3 ACTION trial in H3 K27M glioma moves toward an interim analysis in 1H 2027, while a Phase 2 study of JZP3507 in recurrent meningioma advances with promising preclinical data. Positive outcomes could expand Jazz's CNS oncology footprint and potentially accelerate patient access.

Jazz advances ACTION Phase 3 for Modeyso in H3 K27M glioma; primary endpoint OS.
Trial randomizes 1:1:1 to placebo, once-weekly, or twice-weekly dosing.
Interim analysis planned in 1H 2027; potential earlier access if favorable.
Phase 2 JZP3507 in recurrent meningioma; nanomolar potency reported.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Jazz Advances Modeyso Phase 3 for rare brain cancer with near-term SNO focus

Jazz to acquire Actio Biosciences, expanding rare epilepsy pipeline with ABS-1230

Jazz to Acquire Actio Biosciences to Expand KCNT1 Epilepsy Franchise

Jazz Pharmaceuticals Raises FY2026 Guidance Amid Moderate Earnings Shift

Jazz PT hike on Ziihera uptake signals near- and long-term upside